A Phase 1 Open-Label Study of the Safety of Intravenous Allogeneic Neonatal Mesenchymal Cells (nMSCs) in Young Adult (1A) and Pediatric (1B) Patients With Dilated Cardiomyopathy (DCM)
Abroad (travel likely)RecruitingPHASE1
Conditions
Dilated Cardiomyopathy
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Grady Memorial Hospital, Atlanta, Georgia, United States
Contact: Study coordinator (William Mahle, MD)Contact: Principal Investigator (William Mahle, MD)Hughes Spalding Children's Hospital, Atlanta, Georgia, United States
Contact: Study coordinator (William Mahle, MD)Contact: Principal Investigator (William Mahle, MD)Emory University Hospital, Atlanta, Georgia, United States
Contact: Study coordinator (William Mahle, MD)Contact: Principal Investigator (William Mahle, MD)Arthur M. Blank Hospital, Atlanta, Georgia, United States
Contact: Study coordinator (William Mahle, MD)Contact: Principal Investigator (William Mahle, MD)Scottish Rite Children's Hospital, Atlanta, Georgia, United States
Contact: Study coordinator (William Mahle, MD)Contact: Principal Investigator (William Mahle, MD)
Study leads
William Mahle, MD
Principal Investigator
Emory University